India Pharma Outlook Team | Thursday, 06 August 2026
Biocon delivered a strong start to FY27 with a sharp rise in earnings. The company's Q1 profit jumped four times year-on-year, supported by steady biosimilars demand.
Revenue also increased, reflecting healthy growth across its key business segments. The company expects this momentum to continue as new products gain market share and manufacturing capacity expands.
The Bengaluru-based biopharmaceutical company reported consolidated revenue of INR 4,336 crore, up 10 percent from INR 3,940 crore in the same quarter last year. Consolidated net profit rose to INR 141 crore, compared to INR 35 crore a year ago.
The strong quarterly performance was mainly driven by Biocon Biologics, which continued to record healthy sales across major international markets.
"Biocon has entered FY27 with a clear focus on translating our strategic investments into sustainable growth. A favourable policy environment for biosimilars together with our expanded manufacturing capabilities in the US reinforce our confidence in the long-term opportunities across North America, our biggest market," said Kiran Mazumdar-Shaw, Executive Chairperson, Biocon.
Biocon's biosimilars business remained the biggest contributor during the quarter. Biocon Biologics reported revenue of INR 2,855 crore, registering a 16 percent year-on-year increase. The company said demand remained strong across developed and emerging markets. New product launches also supported overall sales.
A major highlight was the successful launch of denosumab biosimilars in the United States. The launch strengthened the company's presence in one of the world's largest pharmaceutical markets. The management said the product received encouraging customer response. It expects higher contributions from the launch in the coming quarters.
Also Read: AI in Drug Discovery and Development: From Lab to Commercial Market
Apart from higher sales, lower interest expenses helped improve earnings during the quarter. The company benefited from a reduction in finance costs after strengthening its balance sheet. This supported a sharp improvement in net profit despite moderate revenue growth.
Management said operational performance remained stable across business segments. The company also maintained focus on improving efficiencies and expanding manufacturing capabilities. These measures are expected to support future growth while meeting increasing global demand.
Biocon remains confident about future growth opportunities. The company believes rising demand for affordable biologic medicines will continue to create opportunities worldwide. Management highlighted ongoing investments in manufacturing expansion and product development. It also expects a supportive policy environment for biosimilars across major markets.
The company plans to strengthen its global portfolio with additional launches over the next few years. These launches are expected to support revenue growth and improve market presence. Biocon said it remains focused on innovation, expanding patient access, and delivering sustainable growth. With improving profitability and a growing biosimilar portfolio, the company enters the rest of FY27 on a strong footing.
